52 research outputs found
CO2-driven compromises to marine life along the Chilean coast
CO2-driven compromises to marine life were examined along the Chilean sector of the Humboldt Current System, a particularly vulnerable hypoxic and upwelling area, applying the Respiration index (RI = log10 pO2/pCO2) and the pH-dependent aragonite saturation (Ω) to delineate the water masses where aerobic and calcifying organisms are stressed. There was a remarkable negative relationship between oxygen concentration and pH or pCO2 in the studied area, with the subsurface hypoxic Equatorial Subsurface Waters extending from 100 m to about 300 m depth and supporting elevated pCO2 values. The RI reached a minimum at about 200 m depth and decreased towards the Equator. Increased pCO2 in the hypoxic water layer reduced the RI values by as much as 0.59 RI units, with the upper water layer that presents conditions suitable for aerobic life (RI>0.7) declining by half between 42° S and 28° S. The intermediate waters hardly reached those stations closer to the equator so that the increased pCO2 lowered pH and the saturation of aragonite. A significant fraction of the water column along the Chilean sector of the Humboldt Current System suffers from CO2-driven compromises to biota, including waters corrosive to calcifying organisms, stress to aerobic organisms or both. The habitat free of CO2-driven stresses was restricted to the upper mixed layer and to small water parcels at about 1000 m depth. pCO2 acts as a hinge connecting respiratory and calcification challenges expected to increase in the future, resulting in a spread of the challenges to aerobic organisms. © Author(s) 2008.This is a contribution to the Humboldt-2009 project, funded by the Spanish Ministry of Science and Innovation (ref. CTM2009-02497-E/MA) and was also supported by funding from the LINCGlobal (PUC-CSIC).Peer Reviewe
Corrigendum: Resolving the abundance and air-sea fluxes of airborne microorganisms in the North Atlantic Ocean
We found an implementation error in the calculation of the deposition velocity (vd) which, in turn, affected all the estimated vd-depending parameters (deposition flux, residence time, and traveled distance by microorganisms). Deposition fluxes are now somewhat lower than previously estimated, resulting in residence times and traveled distances longer than those previously estimated. In addition, the spray fluxes were calculated using a spray generation function (dF/dr0) valid for droplets of radii between 0.5 and 12 μm proposed by Blanchard (1963) and Gathman (1982) as corrected by Andreas et al. (1995). However, in the calculation of dF/dr0, we exceeded this valid range of radii given that we included droplets with radii from 0.2 μm according to the small size of some microbial cells. Thus, a different formulation of dF/dr0, developed by Gong (2003), is now used for the estimation of spray fluxes of microbes, which is valid even for small droplets from a radius of 0.07 μm.
Below, we offer a new corrected version of the paragraphs affected by corrections along the text. In addition, we show corrected versions of Figure 1 (forward trajectories according residence times), Figure 3 (deposition velocity values), Figure 5 (spray and deposition fluxes), Figure 6 (Net fluxes), and Table 1. The authors apologize for the errors in the estimates reported in the original manuscript. These corrections only affect the magnitude of some of the reported variables and even though they do not change the scientific conclusions of the article they are reported here for accuracy and reproducibility.En prens
Response to Comment on >dilution limits dissolved organic carbon utilization in the deep ocean>
Our recent finding that dilution limits dissolved organic carbon (DOC) utilization in the deep ocean has been criticized based on the common misconception that lability equates to rapid and complete utilization. Even when considering the redefinition of recalcitrant DOC recently proposed by Jiao et al., the dilution hypothesis best explains our experimental observations.This is a contribution to the MALASPINA Expedition 2010 project, funded by the CONSOLIDER-Ingenio 2010 program of the Spanish Ministry of Economy and Competitiveness (ref. CSD2008-00077)Peer Reviewe
DNA hypomethylation affects cancer-related biological functions and genes relevant in neuroblastoma pathogenesis
Neuroblastoma (NB) pathogenesis has been reported to be closely associated with numerous genetic alterations. However, underlying DNA methylation patterns have not been extensively studied in this developmental malignancy. Here, we generated microarray-based DNA methylation profiles of primary neuroblastic tumors. Stringent supervised differential methylation analyses allowed us to identify epigenetic changes characteristic for NB tumors as well as for clinical and biological subtypes of NB. We observed that gene-specific loss of DNA methylation is more prevalent than promoter hypermethylation. Remarkably, such hypomethylation affected cancer-related biological functions and genes relevant to NB pathogenesis such as CCND1, SPRR3, BTC, EGF and FGF6. In particular, differential methylation in CCND1 affected mostly an evolutionary conserved functionally relevant 3′ untranslated region, suggesting that hypomethylation outside promoter regions may play a role in NB pathogenesis. Hypermethylation targeted genes involved in cell development and proliferation such as RASSF1A, POU2F2 or HOXD3, among others. The results derived from this study provide new candidate epigenetic biomarkers associated with NB as well as insights into the molecular pathogenesis of this tumor, which involves a marked gene-specific hypomethylation
Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma
<p>Abstract</p> <p>Background</p> <p>The chromodomain, helicase DNA-binding protein 5 (CHD5) is a potential tumor suppressor gene located on chromosome 1p36, a region recurrently deleted in high risk neuroblastoma (NB). Previous data have shown that <it>CHD5 </it>mRNA is present in normal neural tissues and in low risk NB, nevertheless, the distribution of CHD5 protein has not been explored. The aim of this study was to investigate CHD5 protein expression as an immunohistochemical marker of outcome in NB. With this purpose, CHD5 protein expression was analyzed in normal neural tissues and neuroblastic tumors (NTs). <it>CHD5 </it>gene and protein expression was reexamined after induction chemotherapy in a subset of high risk tumors to identify potential changes reflecting tumor response.</p> <p>Results</p> <p>We provide evidence that CHD5 is a neuron-specific protein, absent in glial cells, with diverse expression amongst neuron types. Within NTs, CHD5 immunoreactivity was found restricted to differentiating neuroblasts and ganglion-like cells, and absent in undifferentiated neuroblasts and stromal Schwann cells. Correlation between protein and mRNA levels was found, suggesting transcriptional regulation of <it>CHD5</it>. An immunohistochemical analysis of 90 primary NTs highlighted a strong association of CHD5 expression with favorable prognostic variables (age at diagnosis <12 months, low clinical stage, and favorable histology; P < 0.001 for all), overall survival (OS) (P < 0.001) and event-free survival (EFS) (P < 0.001). Multivariate analysis showed that CHD5 prognostic value is independent of other clinical and biologically relevant parameters, and could therefore represent a marker of outcome in NB that can be tested by conventional immunohistochemistry. The prognostic value of CHD5 was confirmed in an independent, blinded set of 32 NB tumors (P < 0.001).</p> <p>Reactivation of <it>CHD5 </it>expression after induction chemotherapy was observed mainly in those high risk tumors with induced tumor cell differentiation features. Remarkably, these NB tumors showed good clinical response and prolonged patient survival.</p> <p>Conclusions</p> <p>The neuron-specific protein CHD5 may represent a marker of outcome in NB that can be tested by conventional immunohistochemistry. Re-establishment of CHD5 expression induced by chemotherapy could be a surrogate marker of treatment response.</p
Description of two cultivated and two uncultivated new Salinibacter species, one named following the rules of the bacteriological code: Salinibacter grassmerensis sp. nov.; and three named following the rules of the SeqCode: Salinibacter pepae sp. nov., Salinibacter abyssi sp. nov., and Salinibacter pampae sp. nov.
Current -omics methods allow the collection of a large amount of information that helps in describing the microbial diversity in nature. Here, and as a result of a culturomic approach that rendered the collection of thousands of isolates from 5 different hypersaline sites (in Spain, USA and New Zealand), we obtained 21 strains that represent two new Salinibacter species. For these species we propose the names Salinibacter pepae sp. nov. and Salinibacter grassmerensis sp. nov. (showing average nucleotide identity (ANI) values < 95.09% and 87.08% with Sal. ruber M31T, respectively). Metabolomics revealed species-specific discriminative profiles. Sal. ruber strains were distinguished by a higher percentage of polyunsaturated fatty acids and specific N-functionalized fatty acids; and Sal. altiplanensis was distinguished by an increased number of glycosylated molecules. Based on sequence characteristics and inferred phenotype of metagenome-assembled genomes (MAGs), we describe two new members of the genus Salinibacter. These species dominated in different sites and always coexisted with Sal. ruber and Sal. pepae. Based on the MAGs from three Argentinian lakes in the Pampa region of Argentina and the MAG of the Romanian lake Fără Fund, we describe the species Salinibacter pampae sp. nov. and Salinibacter abyssi sp. nov. respectively (showing ANI values 90.94% and 91.48% with Sal. ruber M31T, respectively). Sal. grassmerensis sp. nov. name was formed according to the rules of the International Code for Nomenclature of Prokaryotes (ICNP), and Sal. pepae, Sal. pampae sp. nov. and Sal. abyssi sp. nov. are proposed following the rules of the newly published Code of Nomenclature of Prokaryotes Described from Sequence Data (SeqCode). This work constitutes an example on how classification under ICNP and SeqCode can coexist, and how the official naming a cultivated organism for which the deposit in public repositories is difficult finds an intermediate solution.This study was funded by the Spanish Ministry of Science, Innovation and Universities projects PGC2018-096956-B-C41, RTC-2017-6405-1 and PID2021-126114NB-C42, which were also supported by the European Regional Development Fund (FEDER). RRM acknowledges the financial support of the sabbatical stay at Georgia Tech and HelmholzZentrum München by the grants PRX18/00048 and PRX21/00043 respectively also from the Spanish Ministry of Science, Innovation and Universities. This research was carried out within the framework of the activities of the Spanish Government through the “Maria de Maeztu Centre of Excellence” accreditation to IMEDEA (CSIC-UIB) (CEX2021-001198). KTK’s research was supported, in part, by the U.S. National Science Foundation (Award No. 1831582 and No. 2129823). IMG. AC and HLB were financially supported by a grant of the Ministry of Research, Innovation and Digitization, CNCS/CCCDI – UEFISCDI, project number PN-III-P4-ID-PCE-2020-1559, within PNCDI III. HLB acknowledges Ocna Sibiului City Hall (Sibiu County, Romania) for granting the access to Fără Fund Lake and A. Baricz and D.F. Bogdan for technical support during sampling and sample preparation. MBS thanks Dominion Salt for their assistance in sample Lake Grassmere. MELL acknowledges the financial support of the Argentinian National Scientific and Technical Research Council (Grant CONICET-NSFC 2017 N° IF-2018-10102222-APN-GDCT-CONICET) and the National Geographic Society (Grant # NGS 357R-18). BPH was supported by NASA (award 80NSSC18M0027). TV acknowledges the “Margarita Salas” postdoctoral grant, funded by the Spanish Ministry of Universities, within the framework of Recovery, Transformation and Resilience Plan, and funded by the European Union (NextGenerationEU), with the participation of the University of Balearic Islands (UIB)
The ITS1-5.8S-ITS2 Sequence Region in the Musaceae: Structure, Diversity and Use in Molecular Phylogeny
Genes coding for 45S ribosomal RNA are organized in tandem arrays of up to several thousand copies and contain 18S, 5.8S and 26S rRNA units separated by internal transcribed spacers ITS1 and ITS2. While the rRNA units are evolutionary conserved, ITS show high level of interspecific divergence and have been used frequently in genetic diversity and phylogenetic studies. In this work we report on the structure and diversity of the ITS region in 87 representatives of the family Musaceae. We provide the first detailed information on ITS sequence diversity in the genus Musa and describe the presence of more than one type of ITS sequence within individual species. Both Sanger sequencing of amplified ITS regions and whole genome 454 sequencing lead to similar phylogenetic inferences. We show that it is necessary to identify putative pseudogenic ITS sequences, which may have negative effect on phylogenetic reconstruction at lower taxonomic levels. Phylogenetic reconstruction based on ITS sequence showed that the genus Musa is divided into two distinct clades – Callimusa and Australimusa and Eumusa and Rhodochlamys. Most of the intraspecific banana hybrids analyzed contain conserved parental ITS sequences, indicating incomplete concerted evolution of rDNA loci. Independent evolution of parental rDNA in hybrids enables determination of genomic constitution of hybrids using ITS. The observation of only one type of ITS sequence in some of the presumed interspecific hybrid clones warrants further study to confirm their hybrid origin and to unravel processes leading to evolution of their genomes
Protocolo de cribado, diagnóstico y tratamiento de la enfermedad de Chagas en mujeres embarazadas latinoamericanas y en sus hijos
Malaltia de Chagas; Dones embarassades llatinoamericanes; Salut maternoinfantilEnfermedad de Chagas; Mujeres embarazadas latinoamericanas; Salud maternoinfantilChagas disease; Latin american pregnant women; Maternal and child healthLa malaltia de Chagas (MCH) continua sent un problema important de salut pública. L’OMS estima que en el món hi ha 8 milions de persones infectades per Trypanosoma cruzi, la majoria a l’Amèrica Llatina. En països no endèmics, com és el cas del nostre entorn, l’MCH s’observa en persones infectades que provenen de països endèmics o en infants nascuts en països no endèmics, però la mare dels quals ha estat infectada (transmissió congènita).
A Catalunya, per tal de fer el control i la vigilància de l’MCH, l’any 2010 es va posar en marxa el Programa de prevenció i control de la malaltia de Chagas congènita a Catalunya, coordinat pel Departament de Salut i que inclou el diagnòstic, el control, el seguiment i el tractament de l’MCH congènita dirigits a les dones embarassades i als seus fills. En el marc del Programa, es va elaborar el Protocol de cribratge i diagnòstic de malaltia de Chagas en dones embarassades llatinoamericanes i en els seus fills, que es va editar el 2010. Aquest document va ser fruit de l’esforç conjunt de professionals sanitaris experts en la malaltia, de diferents societats científiques i de professionals del Departament de Salut de la Generalitat de Catalunya, amb el suport del Grup de Treball de Països No Endèmics i del Departament de Control de Malalties Tropicals Oblidades de l’OMS.
El Protocol que es presenta, a més d’incloure les mateixes línies que la primera edició, disposa d’actualitzacions de diferents aspectes clínics, de diagnòstic i de vigilància epidemiològica basats en l’experiència i l’evidència observades durant aquests vuit anys del Programa de prevenció i control de la malaltia de Chagas congènita a Catalunya. Durant aquests darrers anys, s’ha reforçat la perspectiva de salut pública en el Programa, en el qual han participat un gran nombre de professionals de la xarxa assistencial i agents comunitaris de salut amb l’objectiu de reduir l’efecte de la transmissió vertical de l’MCH a Catalunya.
La primera part del document recull les característiques clíniques de l’MCH que, encara que és d’aparició relativament recent en el nostre entorn, gràcies a la informació facilitada tant en l’àmbit sanitari com en l’àmbit comunitari durant els últims anys, ha deixat de ser una malaltia oblidada i desconeguda a Catalunya.
En els darrers anys, els avenços i l’experiència en el nostre entorn en el diagnòstic de l’MCH ens han fet arribar a un consens sobre la utilització de mètodes directes moleculars, tal com es descriu en aquest Protocol. Així mateix, la concreció de dades epidemiològiques sobre prevalença d’infecció i incidència de casos de la malaltia ha millorat molt gràcies a la vigilància i notificació de dades recollides en el marc del Programa de prevenció i control de la malaltia de Chagas congènita a Catalunya pels professionals que formen part del Grup de Treball de la Malaltia de Chagas Congènita. En aquest aspecte i per tal de millorar-ne el control s’han incorporat els metges de família i salut comunitària, ja que són uns dels professionals clau que es troben més propers als pacients.
Un aspecte fonamental que es desprèn d’aquest document i del funcionament del Programa és la multidisciplinarietat. El repte del sistema de salut i de la vigilància de la salut pública és la coordinació i el treball dels professionals de diferents àmbits sanitaris, com poden ser els ginecòlegs, els microbiòlegs, els llevadors, els pediatres d’atenció primària i hospitalària, els metges de família i salut comunitària, el personal d’infermeria, els infectòlegs, els epidemiòlegs i els agents de salut comunitària que treballen de manera conjunta per a l’assoliment de l’objectiu plantejat.
El present Protocol constitueix un document eminentment pràctic, mitjançant el qual els professionals sanitaris disposen dels elements essencials per a la realització del cribratge en la dona embarassada. A partir d’aquest Protocol s’espera també aconseguir la detecció i el tractament precoç dels casos d’MCH en la població pediàtrica, nadons i altres fills a Catalunya, amb l’objectiu últim de millorar la salut maternoinfantil a Catalunya.La enfermedad de Chagas (ECH) sigue siendo un problema importante de salud pública. La OMS estima que en el mundo hay 8 millones de personas infectadas por Trypanosoma cruzi, la mayoría en América Latina. En países no endémicos, como es el caso de nuestro entorno, la ECH se observa en personas infectadas que provienen de países endémicos o en niños nacidos en países no endémicos, pero cuya madre ha sido infectada (transmisión congénita).
En Cataluña, para hacer el control y la vigilancia de la ECH, en 2010 se puso en marcha el Programa de prevención y control de la enfermedad de Chagas congénita en Cataluña, coordinado por el Departamento de Salud y que incluye el diagnóstico, el control, el seguimiento y el tratamiento de la ECH congénita dirigidos a las mujeres embarazadas y a sus hijos. En el marco del Programa, se elaboró el Protocolo de cribado y diagnóstico de enfermedad de Chagas en mujeres embarazadas latinoamericanas y en sus hijos, que se editó en 2010. Este documento fue fruto del esfuerzo conjunto de profesionales sanitarios expertos en la enfermedad, de diferentes sociedades científicas y de profesionales del Departamento de Salud de la Generalidad de Cataluña, con el apoyo del Grupo de Trabajo de Países No Endémicos y del Departamento de Control de Enfermedades Tropicales Olvidadas de la OMS.
El Protocolo que se presenta, además de incluir las mismas líneas que la primera edición, dispone de actualizaciones de diferentes aspectos clínicos, de diagnóstico y de vigilancia epidemiológica basados en la experiencia y la evidencia observadas durante estos ocho años del Programa de prevención y control de la enfermedad de Chagas congénita en Cataluña. Durante estos últimos años, se ha reforzado la perspectiva de salud pública en el Programa, en el que han participado un gran número de profesionales de la red asistencial y agentes comunitarios de salud con el objetivo de reducir el efecto de la transmisión vertical del ECH en Cataluña.
La primera parte del documento recoge las características clínicas de la ECH que, aunque es de aparición relativamente reciente en nuestro entorno, gracias a la información facilitada tanto en el ámbito sanitario como en el ámbito comunitario durante los últimos años, ha dejado de ser una enfermedad olvidada y desconocida en Cataluña.
En los últimos años, los avances y la experiencia en nuestro entorno en el diagnóstico de la ECH nos han hecho llegar a un consenso sobre la utilización de métodos directos moleculares, tal como se describe en el presente Protocolo. Asimismo, la concreción de datos epidemiológicos sobre prevalencia de infección e incidencia de casos de la enfermedad ha mejorado mucho gracias a la vigilancia y notificación de datos recogidos en el marco del Programa de prevención y control de la enfermedad de Chagas congénita en Cataluña por los profesionales que forman parte del Grupo de Trabajo de la Enfermedad de Chagas Congénita. En este aspecto y para mejorar su control se han incorporado los médicos de familia y salud comunitaria, ya que son unos de los profesionales clave que se encuentran más cercanos a los pacientes.
Un aspecto fundamental que se desprende de este documento y del funcionamiento del Programa es la multidisciplinariedad. El reto del sistema de salud y de la vigilancia de la salud pública es la coordinación y el trabajo de los profesionales de diferentes ámbitos sanitarios, como pueden ser ginecólogos, microbiólogos, comadrones, pediatras de atención primaria y hospitalaria, médicos de familia y salud comunitaria, personal de enfermería, infectólogos, epidemiólogos y agentes de salud comunitaria que trabajan de manera conjunta para el logro del objetivo planteado.
El presente Protocolo constituye un documento eminentemente práctico, mediante el cual los profesionales sanitarios disponen de los elementos esenciales para la realización del cribado en la mujer embarazada. A partir de este Protocolo se espera también conseguir la detección y el tratamiento precoz de los casos de ECH en la población pediátrica, bebés y otros hijos en Cataluña, con el objetivo último de mejorar la salud maternoinfantil en Cataluña.Chagas disease (CHD) continues to be a major public health problem. The WHO estimates that there are 8 million people in the world infected with Trypanosoma cruzi, the majority in Latin America. In non-endemic countries, as is the case in our environment, CHD is seen in infected people who come from endemic countries or children born in non-endemic countries, but whose mother has been infected (congenital transmission).
In Catalonia, in order to control and monitor the CHD, in 2010 the Program for the Prevention and Control of Congenital Chagas' Disease in Catalonia was launched, coordinated by the Department of Health and includes diagnosis, control, follow-up and treatment of congenital CHD directed at pregnant women and their children. Within the framework of the Program, the Protocol for the Screening and Diagnosis of Chagas' Disease in Latin American pregnant women and their children was prepared, which was published in 2010. This document was the result of the joint effort of health professionals who are experts in the disease, of different scientific societies and professionals of the Department of Health of the Government of Catalonia, with the support of the Working Group of Non-endemic Countries and the Department of Control of Forgotten Tropical Diseases of WHO.
The Protocol that is presented, in addition to including the same lines as the first edition, has updates on different clinical, diagnostic and epidemiological surveillance aspects based on the experience and evidence observed during these eight years of the Prevention and Control Program. Congenital Chagas disease in Catalonia. During these last years, the perspective of public health in the Program has been reinforced, in which a large number of professionals of the health care network and community health agents have participated with the aim of reducing the effect of the vertical transmission of CHD in Catalonia.
The first part of the document includes the clinical characteristics of the CHD that, although it is relatively recent in our environment, thanks to the information provided both in the health field and in the community in recent years, has ceased to be a disease forgotten and unknown in Catalonia.
In recent years, the advances and experience in our environment in the diagnosis of CHD have led us to reach a consensus on the use of direct molecular methods, as described in this Protocol. Likewise, the specification of epidemiological data on prevalence of infection and incidence of cases of the disease has improved greatly thanks to the monitoring and reporting of data collected within the framework of the Program for the Prevention and Control of Congenital Chagas' Disease in Catalonia by professionals. that are part of the Working Group on Congenital Chagas Disease. In this aspect and to improve their control, family doctors and community health have been incorporated, since they are one of the key professionals who are closest to patients.
A fundamental aspect that emerges from this document and the operation of the Program is multidisciplinarity. The challenge of the health system and public health surveillance is the coordination and work of professionals from different health areas, such as gynecologists, microbiologists, midwives, pediatricians of primary and hospital care, family physicians and community health , nurses, infectious disease specialists, epidemiologists and community health workers who work together to achieve the stated objective.
This Protocol is an eminently practical document, through which health professionals have the essential elements for carrying out screening in pregnant women. Based on this Protocol, it is also expected to achieve the detection and early treatment of cases of CHD in the pediatric population, babies and other children in Catalonia, with the ultimate goal of improving maternal and child health in Catalonia
Description of two cultivated and two uncultivated new Salinibacter species, one named following the rules of the bacteriological code: Salinibacter grassmerensis sp. nov.; and three named following the rules of the SeqCode: Salinibacter pepae sp. nov., Salinibacter abyssi sp. nov., and Salinibacter pampae sp. nov.
DATA AVAILABILITY : All data is publicly available in research repositories.Current ‐omics methods allow the collection of a large amount of information that helps in describing the
microbial diversity in nature. Here, and as a result of a culturomic approach that rendered the collection of
thousands of isolates from 5 different hypersaline sites (in Spain, USA and New Zealand), we obtained 21
strains that represent two new Salinibacter species. For these species we propose the names Salinibacter pepae
sp. nov. and Salinibacter grassmerensis sp. nov. (showing average nucleotide identity (ANI) values < 95.09%
and 87.08% with Sal. ruber M31T, respectively). Metabolomics revealed species‐specific discriminative profiles.
Sal. ruber strains were distinguished by a higher percentage of polyunsaturated fatty acids and specific Nfunctionalized
fatty acids; and Sal. altiplanensis was distinguished by an increased number of glycosylated molecules.
Based on sequence characteristics and inferred phenotype of metagenome‐assembled genomes (MAGs),
we describe two new members of the genus Salinibacter. These species dominated in different sites and always
coexisted with Sal. ruber and Sal. pepae. Based on the MAGs from three Argentinian lakes in the Pampa region
of Argentina and the MAG of the Romanian lake Fără Fund, we describe the species Salinibacter pampae sp. nov.
and Salinibacter abyssi sp. nov. respectively (showing ANI values 90.94% and 91.48% with Sal. ruber M31T, respectively). Sal. grassmerensis sp. nov. name was formed according to the rules of the International Code for
Nomenclature of Prokaryotes (ICNP), and Sal. pepae, Sal. pampae sp. nov. and Sal. abyssi sp. nov. are proposed
following the rules of the newly published Code of Nomenclature of Prokaryotes Described from Sequence Data
(SeqCode). This work constitutes an example on how classification under ICNP and SeqCode can coexist, and
how the official naming a cultivated organism for which the deposit in public repositories is difficult finds an
intermediate solution.The Spanish Ministry of Science, Innovation and Universities projects which were supported by the European Regional Development Fund (FEDER), in part by the U.S. National Science Foundation, a grant of the Ministry of Research, Innovation and Digitization, CNCS/CCCDI – UEFISCDI, the Argentinian National Scientific and Technical Research Council, the National Geographic Society, NASA, and the “Margarita Salas” postdoctoral grant, funded by the Spanish Ministry of Universities, within the framework of Recovery, Transformation and Resilience Plan, and funded by the European Union.http://www.elsevier.com/locate/syapmam2024BiochemistryForestry and Agricultural Biotechnology Institute (FABI)GeneticsMicrobiology and Plant PathologySDG-15:Life on lan
- …